Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period

Peptides

Volumn 18, Issue 8, 1997, Pages 1131-1137

  Wu, Joyce Y ^a   Henins, Karin A ^a   Gressens, Pierre ^b   Gozes, Illana ^c   Fridkin, Mati ^d   Brenneman, Douglas E ^a   Hill, Joanna M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c TEL AVIV UNIVERSITY   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Developmental milestones; Developmental retardation; Mouse embryos; Neurobehavioral development; Vasoactive intestinal peptide; VIP antagonist

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; BEHAVIOR; BIRTH WEIGHT; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GROWTH RETARDATION; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RIGHTING REFLEX; STARTLE REFLEX;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BODY WEIGHT; EMBRYONIC AND FETAL DEVELOPMENT; EMBRYONIC DEVELOPMENT; FEMALE; GROWTH INHIBITORS; MICE; MOTOR ACTIVITY; NEUROTENSIN; PREGNANCY; RECOMBINANT FUSION PROTEINS; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA;

EID: 0031458241     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00146-0     Document Type: Article

References (45)

1. Brenneman D. E., Eiden L. E. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA. 83:1986;1159-1162.
2. Brenneman D. E., Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:1996;2299-2307.
3. Brenneman D. E., Neale E. A., Foster G. A., d'Autremont S., Westbrook G. L. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104:1987;1603-1610.
4. Brenneman D. E., Nicol T., Warren D., Bowers L. M. Vasoactive intestinal peptide A neurotrophic releasing agent and an astroglial mitogen . J. Neurosci. Res. 25:1990;386-394.
5. Brenneman D. E., Hill J. M., Glazner G. W., Gozes I., Phillips T. W. Interleukin-1alpha and vasoactive intestinal peptide Enigmatic regulation of neuronal survival . Int. J. Dev. Neurosci. 13:1995;187-200.
6. Chneiweiss H., Glowinski J., Premont J. Vasoactive intestinal polypeptide receptors linked to an adenylate cyclase, and their relationship with biogenic amine- and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in primary cultures. J. Neurochem. 44:1985;779-786.
7. Cottrell G. A., Veldhuis H. D., Rostene W. H., de Kloet E. R. Behavioral actions of vasoactive intestinal peptide (VIP). Neuropeptides. 4:1984;331-341.
8. Drucker-Colin R., Bernal-Pedraza J., Fernandez-Cancino F., Oksenberg A. Is vasoactive intestinal peptide (VIP) a sleep factor? Peptides. 5:1984;837-840.
9. Drucker-Colin R., Prosper-Garcia O., Perez-Montfort R., Pacheco M. T. Vasoactive intestinal peptide A possible REM sleep factor . Ann. NY Acad. Sci. 527:1988;627-630.
10. Fatatis A., Holtzclaw L. A., Avidor R., Brenneman D. E., Russell J. T. Vasoactive intestinal peptide increases intracellular calcium in astroglia Synergism with alpha-adrenergic receptors . Proc. Natl. Acad. Sci. USA. 91:1994;2036-2040.
11. Ferron A., Siggins G. R., Bloom F. E. Vasoactive intestinal polypeptide acts synergistically with norepinephrine to depress spontaneous discharge rate in cerebral cortical neurons. Proc. Natl. Acad. Sci. USA. 82:1985;8810-8812.
12. Fox W. M. Reflex-ontogeny and behavioral development of the mouse. Anim. Behav. 13:1965;234-241.
13. Gressens P., Hill J. M., Gozes I., Fridkin M., Brenneman D. E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 362:1993;155-158.
14. Gressens P., Hill J. M., Paindaveine B., Gozes I., Fridkin M., Brenneman D. E. Severe microcephaly induced by blockage of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94:1994;2020-2027.
15. Glowa J. R., Panlilio L. V., Brenneman D. E., Gozes I., Fridkin M., Hill J. M. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570:1992;49-53.
16. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I. E., Davidson A., Rubinrout S., Fridkin M., Brenneman D. E. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273:1995;161-167.
17. Gozes I., McCune S. K., Jacobsen L., Warren D., Moody T. W., Fridkin M., Brenneman D. E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257:1991;959-966.
18. Gozes I., Meltzer E., Rubinrout S., Brenneman D. E., Fridkin M. Vasoactive intestinal peptide potentiates sexual behavior Inhibition by novel antagonist . Endocrinology. 125:1989;2945-2949.
19. Gozes Y., Brenneman D. E., Fridkin M., Asofsky R., Gozes I. A VIP antagonist distinguishes VIP receptors in spinal cord cells and lymphocytes. Brain Res. 540:1991;319-321.
20. Hashimoto Y., Mitzutani M. Early neurobehavioral disorders in the micrencephalic offspring induced by prenatal treatment with N-methyl-N-nitrosourea or methylazoxymethanol. J. Vet. Med. Sci. 53:1991;643-649.
21. Hill J. M., Agoston D. V., Gressens P., McCune S. K. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain Relation to ontogenic events . J. Comp. Neurol. 342:1994;186-205.
22. Hill J. M., Gozes I., Hill J. L., Fridkin M., Brenneman D. E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides. 12:1991;187-192.
23. Hill J. M., Harris A., Hilton-Clarke D. I. Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain. Neuroscience. 48:1992;925-932.
24. Hill J. M., McCune S. K., Alvero R. J., Glazner G. W., Henins K. A., Stanziale S. F., Keimowitz J. R., Brenneman D. E. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J. Clin. Invest. 97:1996;202-208.
25. Hill J. M., Mervis R. F., Avidor R., Moody T. W., Brenneman D. E. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 603:1993;222-233.
26. Hill J. M., Mervis R. F., Politi J., McCune S. K., Gozes I., Fridkin M., Brenneman D. E. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. NY Acad. Sci. 739:1994;211-225.
27. Hösli E., Hösli L. Autoradiographic localization of binding sites for vasoactive intestinal peptide and angiotensin II on neurons and astrocytes of cultured rat central nervous system. Neuroscience. 31:1989;463-470.
28. Ishihara T., Shigemoto R., Mori K., Takahashi K., Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8:1992;811-819.
29. Itoh S., Katsuura G., Yoshikawa K. Hypermotility induced by vasoactive intestinal peptide in the rat Its reciprocal action to cholecystokinin octapeptide . Peptides. 6:1985;53-57.
30. Johnston M. V., Coyle J. T. Effects of fetal treatment with methylazoxymethanol acetate at various gestational dates on the neurochemistry of the adult neocortex of the rat. J. Neurochem. 36:1981;124-128.
31. Jonsson G., Hallman H. Effects of prenatal methylazoxymethanol acetate treatment on the development of central monoamine neurons. Brain Res. 254:1991;513-530.
32. Kaufman, M. H., Ed. The atlas of mouse development. New York: Academic Press; 1992.
33. Kulkosky P. J., Doyle J. S., Cook V. I., Glazner G. W. Vasoactive intestinal peptide Behavioral effects in the rat and hamster . Pharmacol. Biochem. Behav. 34:1989;387-393.
34. Lai H., Quock R. M., Makous W., Horita A., Jen L. S. Methylazoxymethanol acetate Effect of postnatal injection on brain amines and behavior . Pharmacol. Biochem. Behav. 8:1978;251-257.
35. 2 receptor Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide . FEBS Lett. 334:1993;3-8.
36. Magistretti P. J., Manthorpe M., Bloom F. E., Varon S. Functional receptors for vasoactive intestinal polypeptide in cultured astroglia from neonatal rat brain. Regul. Pept. 6:1983;71-80.
37. Magistretti P. J., Schorderet M. VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex. Nature. 308:1984;280-282.
38. Martin J.-L., Feinstein L. D., Yu N., Sorg O., Rossier C., Magistretti P. J. VIP receptor subtypes in mouse cerebral cortex Evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes . Brain Res. 587:1992;1-12.
39. Olah Z. ; Lehel, Cs.; Anderson, W. B.; Brenneman, D. E.; Agoston, D. V. Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J. Neurosci. Res. 39:1994;355-363.
40. Peeters L. L. The effect of early maternal maladaptation on fetal growth. J. Perinat. Med. 22:(Suppl. 1):1994;9-17.
41. Riou F., Cespuglio R., Jovet M. Endogenous peptides and sleep in the rat. III. The hypnogenic properties of vasoactive intestinal polypeptide. Neuropeptides. 2:1982;265-277.
42. Rodier P. M. Correlations between prenatally-induced alterations in CNS populations and postnatal function. Teratology. 16:1977;235-246.
43. Schaad N. C., Vanecek J., Rodriguez I. R., Klein D. C., Holtzclaw L., Russell J. T. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx Evidence for involvement of a cyclic GMP-dependent mechanism . Mol. Pharmacol. 47:1995;923-933.
44. Sreedharan S. P., Patel D. R., Huang J. X., Goetzl E. J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide. Biochem. Biophys. Res. Commun. 193:1993;546-553.
45. Woods S. C., West D. B., Stein L. J., McKay L. D., Lotter E. C., Porte S. G., Kenney N. J., Porte D. Jr. Peptides and the control of meal size. Diabetologia. 20:1981;303-310.